Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
Manual de preservación de bacterias
No full textFil: Prieto, Mónica. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Fil: Martínez, Claudia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Fil: Diangolo, Gastón. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio de Bacteriología Especial; Argentina.Los microorganismos han sido históricamente empleados en la producción de medicamentos, en la producción de alimentos y en la elaboración de reactivos, entre otras aplicaciones. También han sido implementados como agentes biorremedadores para la protección ambiental y su utilización ha incrementado con el avance de la biotecnología. Estas aplicaciones han fortalecido la necesidad de preservar y mantener los cultivos microbianos de manera tal que las propiedades que los hacen importantes permanezcan estables a lo largo del tiempo en articulación con la normativa vigente y la evidencia científica que requieren la implementación de sistemas de gestión de calidad en laboratorios de análisis microbiológicos para asegurar la trazabilidad de los resultados que se generan.
En este sentido se ha desarrollado el presente manual que contiene tanto el desarrollo conceptual, como la descripción necesaria para la manipulación de las cepas de referencia, y también se describen los métodos de preservación a corto y largo plazo. Siendo el objetivo del mismo es brindar el apoyo necesario para la gestión de la calidad de análisis microbiológicos como herramienta valiosa para la investigación científica, el estudio de la biodiversidad, la investigación epidemiológica y la industria
Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina
No full textFil: Pontoriero, A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Baumeister, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Campos, Ana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Avaro, Martín. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Benedetti, Estefanía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Dattero, María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; ArgentinaFil: Zylberman, Vanesa. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina.Fil: Sanguineti, Santiago. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Higa, Sandra V. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Cerutti, María L. Universidad Nacional de San Martín. Centro de Rediseño e Ingenieria de Proteínas (CRIP); Buenos Aires, Argentina.Fil: Morrone Seijo, Susana M. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina.Fil: Pardo, Romina. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina.Fil: Muñoz, Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Buenos Aires, Argentina.Fil: Acuña Intrieri, María E. Universidad Nacional de San Martín. Centro de Rediseño e Ingenieria de Proteínas (CRIP); Buenos Aires, Argentina.Fil: Alzogaray, Vanina A. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Berguer, Paula M. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Bocanera, Laura. mAbxience; Buenos Aires, Argentina.Fil: Bukata, Lucas. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Bustelo, Marina S. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Colonna, Mariana. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Correa, Elisa. mAbxience; Buenos Aires, Argentina.Fil: Cragnaz, Lucía. mAbxience; Buenos Aires, Argentina.Fil: Dellafiore, María. mAbxience; Buenos Aires, Argentina.Fil: Foscaldi, Sabrina. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: González, Joaquín V. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Guerra, Luciano L. mAbxience; Buenos Aires, Argentina.Fil: Klinke, Sebastián. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Labanda, María S. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Lauché, Constanza. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: López, Juan C. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Martínez, Anabela M. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Otero, Lisandro H. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Peyric, Elías H. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Ponziani, Pablo F. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Ramondino, Romina. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Rinaldi, Jimena. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Rodríguez, Santiago. mAbxience; Buenos Aires, Argentina.Fil: Russo, Javier E. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Russo, Mara L. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Virología. Servicio de Virosis Respiratorias. Centro Nacional de Influenza PAHO/WHO; Argentina.Fil: Saavedra, Soledad L. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Seigelchifer, Mauricio. mAbxience; Buenos Aires, Argentina.Fil: Sosa, Santiago. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.Fil: Vilariño, Claudio. Universidad Nacional de San Martín. Centro de Rediseño e Ingenieria de Proteínas (CRIP); Buenos Aires, Argentina.Fil: López Biscayart, Patricia. Instituto Biológico Argentino S.A.I.C.; Buenos Aires, Argentina.Fil: Corley, Esteban. mAbxience; Buenos Aires, Argentina.Fil: Spatz, Linus. INMUNOVA S.A.; Buenos Aires, Argentina.Fil: Goldbaum, Fernando A. Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBA). Fundación Instituto Leloir. Laboratorio de Inmunología y Microbiología Molecular; Buenos Aires, Argentina.The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab')2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina
Seroprevalence of leptospiral antibodies in rodents from riverside communities of Santa Fe, Argentina
No full textLeptospirosis is a zoonotic disease that can be transmitted by contact with the urine of infected mammals. Rodents play a mayor role in the transmission of leptospires to humans. The province of Santa Fe reports the greatest number of cases in Argentina. Yet, in this region, there are still knowledge gaps regarding the diversity of rodent species that may be hosts of pathogenic leptospires. The aims of this study were to evaluate the presence of leptospiral antibodies in rodents from three riverside communities of Santa Fe, and to identify factors associated with leptospiral infection
Characterisation of ST25 NDM-1-producing Acinetobacter spp. strains leading the increase in NDM-1 emergence in Argentina
Full text linkFil: Rodgers, Deja. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Pasteran, Fernando. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Calderon, Manuel. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Jaber, Sara. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Traglia, Germán M. Universidad de La República. Facultad de Medicina. Instituto de Higiene. Departamento de Desarrollo Biotecnología, Montevideo; Uruguay.Fil: Albornoz, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Vila, Alejandro J. Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET UNR), Rosario; Argentina.Fil: Bonomo, Robert A. Research Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio; Estados Unidos.Fil: Adams, Mark D. The Jackson Laboratory, Farmington, Connecticut; Estados Unidos.Fil: Ramírez, María Soledad. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, Fullerton, California; Estados Unidos
Speckle tracking echocardiography in the indeterminate form of Chagas disease
No full textFil: Cianciulli, Tomás Francisco. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Albarracín, Gerardo Ariel. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Napoli Llobera, Mariano. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Prado, Nilda Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Saccheri, María Cristina. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Hernández Vásquez, Yolanda María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Méndez, Ricardo José. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Beck, Martín Alejandro. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Baez, Karina Giselle. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Fil: Balletti, Lorena Romina. Hospital of the Government of the City of Buenos Aires "Dr. Cosme Argerich". Division of Cardiology. Echocardiography Laboratory; Argentina.Background: Chagas disease is one of the most common diseases in Latin-America, and cardiac involvement is a significant cause of death. Assessment of myocardial strain may detect early myocardial damage.
Objectives: To determine differences in longitudinal strain using speckle tracking to assess regional and global left ventricular function in patients with the indeterminate form of Chagas disease, in comparison with a control group.
Methods: This is a retrospective matched case-control study, conducted in a single center. We evaluated 45 adult patients with Chagas disease, diagnosed with 2 serological methods, without evidence of cardiac involvement, who were compared with 45 healthy control subjects, who were sex- and age-matched. All patients underwent Doppler echocardiography and longitudinal strain with speckle tracking.
Results: Median age was 59 years, and 60% were female. Echocardiographic parameters were similar in patients with Chagas and control subjects. In patients with Chagas, global strain differed significantly from that of control subjects (-17 vs -20.3, P < .001). Segmental strain showed 7 abnormal segments in patients with Chagas (P < .05).
Conclusions: In patients with the indeterminate form of Chagas disease, global and segmental longitudinal peak systolic strain is reduced compared with healthy subjects, thus suggesting that it could be a sensitive technique to detect early myocardial damage. These findings could provide useful information regarding the pathophysiology of cardiac involvement and understand whether they might have prognostic usefulness or help develop strategies to modify the course and prognosis of patients with Chagas disease. A longitudinal prospective study would be necessary to validate our findings
Simple phenotypic tests to improve accuracy in screening chromosomal and plasmid-mediated colistin resistance in gram-negative bacilli
Full text linkFil: Pasteran, Fernando. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Danze, Diego. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Menocal, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Cabrera, Carla. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Castillo, Ignacio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Albornoz, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Lucero, Celeste. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Rapoport, Melina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Ceriana, Paola. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.CLSI and EUCAST recommends that only broth microdilution (BMD) should be used for routine colistin susceptibility testing, however, it could be difficult to perform in resource-poor settings. The purpose of this study was to evaluate the accuracy of an agar spot test (COL-AS) and a colistin drop test (COL-DT) as compared to BMD. COL-AS and COL-DT were challenged with a collection of 271 Gram-negative bacilli clinical isolates: 195 Enterobacterales (including 63 mcr-1 positive strains), 37 Acinetobacter spp. and 39 Pseudomonas aeruginosa For COL-AS, 3.0μg/ml (final concentration) of colistin was added to a Mueller-Hinton agar plate and subsequently swabbed with a 0.5 McFarland suspension of tested strain within 1cm2 spot. For COL-DT, 10μl of a 16μg/ml colistin solution was dripped on the surface of a Mueller-Hinton agar plate, previously inoculated with a lawn of tested strain (0.5 McFarland). Colistin solution was made either, by dissolving powder or by disk elution in CA-MHB. Overall, 141/271 (52%) isolates were categorized as colistin resistant by reference BMD. COL-AS yielded a categorical agreement (CA) of 95.5% compared to BMD, with 0.7% very major errors and 3.8% major errors. COL-DT yielded a CA of 96.2% compared to BMD, with 0.7% and 0% very major errors and 3.1% and 3.8% major errors, for colistin powder and disk elution solutions, respectively. Most major errors occurred for mcr-1 producing strains with MICs that fluctuated from 2 to 4 μg/ml according to the method used. In conclusion, we developed and validated methods suited to the systematic screening of resistance to colistin in gram negative bacilli.Clinical relevance: colistin continues to be one of the last-line therapeutic options to treat carbapenemase-producing gram negative bacilli. The BMD reference methodology, recommended by current standards for evaluating colistin sensitivity, is difficult to implement in laboratories from low-resource countries. Recently CLSI endorsed two MIC-based alternative methods for testing colistin in Enterobacterales and P. aeruginosa, a colistin broth disk elution (CBDE) and a colistin agar test (CAT).In this work, we propose two simple methodologies, related to CLSI methods, to screen for colistin resistance, with a performance equivalent to the reference method in detecting resistance to colistin, both of plasmid (mcr) and chromosomal nature. Furthermore, the methods validated here allowed a better identification of those producers of mcr producer with borderline MICs. These screening tests can be routinely performed in addition to the tests currently in use, showed long stability during storage and some of them do not require colistin powder as the source of antibiotic, an important limitation in low-resource countries
Genetic Identification and Drug-Resistance Characterization of Mycobacterium tuberculosis Using a Portable Sequencing Device. A Pilot Study
No full textFil: Cervantes, Jorge. Texas Tech University Health Sciences Center. Paul L. Foster School of Medicine; Texas, Estados Unidos.Fil: Yokobori, Noemí. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Hong, Bo-Young. The Jackson Laboratory for Genomic Medicine; Farmington, Estados Unidos.Clinical management of tuberculosis (TB) in endemic areas is often challenged by a lack of resources including laboratories for Mycobacterium tuberculosis (Mtb) culture. Traditional phenotypic drug susceptibility testing for Mtb is costly and time consuming, while PCR-based methods are limited to selected target loci. We herein utilized a portable, USB-powered, long-read sequencing instrument (MinION), to investigate Mtb genomic DNA from clinical isolates to determine the presence of anti-TB drug-resistance conferring mutations. Data analysis platform EPI2ME and antibiotic-resistance analysis using the real time ARMA workflow, identified Mtb species as well as extensive resistance gene profiles. The approach was highly sensitive, being able to detect almost all described drug resistance conferring mutations based on previous whole genome sequencing analysis. Our findings are supportive of the practical use of this system as a suitable method for the detection of antimicrobial resistance genes, and effective in providing Mtb genomic information. Future improvements in the error rate through statistical analysis, drug resistance prediction algorithms and reference databases would make this a platform suited for the clinical setting. The small size, relatively inexpensive cost of the device, as well as its rapid and simple library preparation protocol and analysis, make it an attractive option for settings with limited laboratory infrastructure